# Georgia Research Alliance

> Georgia Research Alliance is a VC fund backing Biotechnology and Health Care. See 106 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Atlanta, United States
- Total investments: 106
- Last investment: Nov 2022
- Lead investor: 91%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/georgia-research-alliance
- X (Twitter): http://twitter.com/ga_res_alliance
- Website: http://gra.org
- Facebook: http://www.facebook.com/GeorgiaResearchAlliance

Georgia Research Alliance is a VC fund in Atlanta focused on Biotechnology and Health Care. The Georgia Research Alliance (GRA) expands research and commercialization capacity in Georgia’s universities to launch new companies, create high-value jobs and transform lives.Since its formation in 1990, GRA has leveraged over $600 million of state funding into:$2.6 billion of direct federal and private investment in Georgia150+ newlylaunched companies 6,000+ high-skill, high-value jobsa portfolio of inventions, processes and technologies that benefit humankindGRA is an independent nonprofit (501c3) organization closely aligned with Georgia’s Department of Economic Development and works with the following partner universities: University of Georgia, Georgia Regents University, Emory University, Clark Atlanta University, Georgia Institute of Technology, Georgia State University, Mercer University and Morehouse School of Medicine.

## Contacts

5 contacts available for Georgia Research Alliance. Shizune tracks 2 team members at Georgia Research Alliance. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/georgia-research-alliance?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 27 | 25% |
| Health Care | 24 | 23% |
| Medical | 17 | 16% |
| Therapeutics | 14 | 13% |
| Life Science | 12 | 11% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 42 | 40% |
| Seed | 4 | 4% |
| Series A | 3 | 3% |
| Debt Financing | 2 | 2% |
| Series B | 1 | 1% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 31 | 29% |
| France | 2 | 2% |
| Australia | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| C. Michael Cassidy | President and CEO | 0 | https://shizune.co/investors/profile/c-michael-cassidy |
| Timothy Murrary | Reviewer | 0 | https://shizune.co/investors/profile/timothy-murrary |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nyra Medical | MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar. | $20M | Series A | Nov 18, 2022 |  |
| EarliTec Diagnostics | EarliTec Diagnostics is a digital health company making earlier identification and treatment for ASD and related disabilities accessible to children everywhere. Developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, EarliTec is pioneering development of biomarkers that helpparents, providers and caregivers understand how a child is viewing the world. | $19.5M | Series A | Feb 10, 2022 |  |
| Oncospherix | OncoSpherix is committed to improving the quality of life and survival in people whose cancers cannot be cured by the standard of care. Most tumors grow faster than their blood supplies, which leads to regions where tumor cells are starved of oxygen, a situation known as hypoxia. Rather than being killed by the hypoxia, tumor cells fight backthrough the expression of master regulatory proteins called hypoxia inducible factors. | $250K | Debt Financing | Sep 01, 2021 |  |
| TendoNova | TendoNova is a medical device manufacturing company that specializes in developing tools for minimally invasive orthopedic procedures that can be performed under ultrasound guidance by physicians. It provides clinicians with modalities that are customizable to the individual patients. The company provides doctors with modalities that are adaptableto specific patient needs without having to incur significant additional costs by delivering micro-invasive equipment meant to perform percutaneous tenotomy under ultrasound guidance in-office. | $250K | Seed | Aug 05, 2021 |  |
| TendoNova | TendoNova is a medical device manufacturing company that specializes in developing tools for minimally invasive orthopedic procedures that can be performed under ultrasound guidance by physicians. It provides clinicians with modalities that are customizable to the individual patients. The company provides doctors with modalities that are adaptableto specific patient needs without having to incur significant additional costs by delivering micro-invasive equipment meant to perform percutaneous tenotomy under ultrasound guidance in-office. | $250K | Debt Financing | Aug 05, 2021 |  |
| Oncospherix | OncoSpherix is committed to improving the quality of life and survival in people whose cancers cannot be cured by the standard of care. Most tumors grow faster than their blood supplies, which leads to regions where tumor cells are starved of oxygen, a situation known as hypoxia. Rather than being killed by the hypoxia, tumor cells fight backthrough the expression of master regulatory proteins called hypoxia inducible factors. | $46.7K | Grant | Aug 02, 2021 |  |
| Oncospherix | OncoSpherix is committed to improving the quality of life and survival in people whose cancers cannot be cured by the standard of care. Most tumors grow faster than their blood supplies, which leads to regions where tumor cells are starved of oxygen, a situation known as hypoxia. Rather than being killed by the hypoxia, tumor cells fight backthrough the expression of master regulatory proteins called hypoxia inducible factors. | $53.3K | Grant | Feb 02, 2021 |  |
| Aviabiotic | Aviabiotic creates probiotics for integrated poultry companies. The probiotic, genetically engineered for thermostability, elimination of antibiotic resistance, and dependence on corn sugar (to protect the environment from recombinant DNA after it has left the chicken), will produce eicosapentanoic acid, a heart-healthy, Omega-3 fatty acid.Genetically engineered Bacillus subtilisspores in the chicken’s small intestine convert conventional poultry feed into helpful Omega-3 fatty acids.While currently in the concept stage, Aviabiotic has the tools to create a functional prototype for further testing purposes. | $20K | Grant | Mar 18, 2020 |  |
| AngioCloud | AngioCloud allows medical professionals to share and analyze 3D vascular images with unprecedented ease and flexibility. As a Cloud-based offering, the software allows any connected device (desktop or mobile) to share the kinds of high-quality images that were only available at a dedicated hospital workstation. This ease of access will speed theplanning of procedures requiring precise sizing, placement, and deployment of medical devices. E-consults, pre-surgical planning, and clinical decision support will greatly benefit from the advent of this technology. | $34.3K | Grant | Mar 02, 2020 |  |
| Neovaccine Strategies | Neovaccine Strategies develops a novel immunotherapeutic reagent to act as a prophylactic against P. aeruginosa. Its technique generates antibodies to the abundant, highly conserved protein EF-Tu. Encouraged by early findings, Neovaccine will test their vaccine on a mouse model in the next phase of development.This technique, the passiveadministration of antibodies, importantly does not require a functioning immune response, making this ideally suited to immunocompromised patients needing protection from this bacterial pathogen. | $24.7K | Grant | Mar 02, 2020 |  |

10 of 106 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together
- [RMI Partners](https://shizune.co/investors/profile/rmi-partners) — VC Fund, 2 deals together
- [Bio/Med Investor Network](https://shizune.co/investors/profile/bio-med-investor-network-2) — VC Fund, 1 deal together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 1 deal together
- [CAM Capital](https://shizune.co/investors/profile/camcapital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does Georgia Research Alliance invest in?

Georgia Research Alliance invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Seed stage. Most of the 106 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Georgia Research Alliance?

Public channels for Georgia Research Alliance include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Georgia Research Alliance?

The team at Georgia Research Alliance includes C. Michael Cassidy (President and CEO) and Timothy Murrary (Reviewer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co